BI-2865 Size:100mg providing more space for adding

providing more space for adding samples

making it suitable for protein solution filtration

pd ul { padding-left: 20px

biofargo-h2{ color:#0056b3

BI-2865 Size:100mg providing more space for addingDescription BI 2865 is a pan KRAS inhibitor disables oncogenic signalling and tumour growth. BI 2865 blocks nucleotide exchange to prevent the activation of wild type KRAS and a broad range of KRAS mutants, including G12A C D F V S, G13C D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth